These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 30871108)

  • 1. BRCA2 and Other DDR Genes in Prostate Cancer.
    Nombela P; Lozano R; Aytes A; Mateo J; Olmos D; Castro E
    Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30871108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides
    Voutsadakis IA; Stravodimou A
    Anticancer Res; 2023 Mar; 43(3):967-981. PubMed ID: 36854505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA-Damage-Repair Gene Alterations in Genitourinary Malignancies.
    Dariane C; Timsit MO
    Eur Surg Res; 2022; 63(4):155-164. PubMed ID: 35944490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.
    Cerrato A; Morra F; Celetti A
    J Exp Clin Cancer Res; 2016 Nov; 35(1):179. PubMed ID: 27884198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roles of the PARP Inhibitor in
    Inoue T; Sekito S; Kageyama T; Sugino Y; Sasaki T
    Cancers (Basel); 2023 May; 15(9):. PubMed ID: 37174127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA.
    Risdon EN; Chau CH; Price DK; Sartor O; Figg WD
    Oncologist; 2021 Jan; 26(1):e115-e129. PubMed ID: 32790034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations.
    Shah S; Rachmat R; Enyioma S; Ghose A; Revythis A; Boussios S
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implications of DNA damage repair alterations for the management of prostate cancer.
    Lozano R; Olmos D; Castro E
    Curr Opin Urol; 2022 May; 32(3):302-310. PubMed ID: 35266912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer.
    Lozano R; Castro E; Aragón IM; Cendón Y; Cattrini C; López-Casas PP; Olmos D
    Br J Cancer; 2021 Feb; 124(3):552-563. PubMed ID: 33106584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations in BRCA2 as Determinants of Therapy Response in Prostate Cancer.
    Hofstad M; Huang EY; Woods A; Yin Y; Desai NB; Raj GV
    Crit Rev Oncog; 2022; 27(1):81-96. PubMed ID: 35993980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review of the prevalence of DNA damage response gene mutations in prostate cancer.
    Lang SH; Swift SL; White H; Misso K; Kleijnen J; Quek RGW
    Int J Oncol; 2019 Sep; 55(3):597-616. PubMed ID: 31322208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in
    Carneiro BA; Collier KA; Nagy RJ; Pamarthy S; Sagar V; Fairclough S; Odegaard J; Lanman RB; Costa R; Taxter T; Kuzel TM; Fan A; Chae YK; Cristofanilli M; Hussain MH; Abdulkadir SA; Giles FJ
    JCO Precis Oncol; 2018; 2():. PubMed ID: 31501807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
    Antonarakis ES; Gomella LG; Petrylak DP
    Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
    Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
    Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Case-Based Clinical Approach to the Investigation, Management and Screening of Families with BRCA2 Related Prostate Cancer.
    King B; McHugh J; Snape K
    Appl Clin Genet; 2021; 14():255-266. PubMed ID: 34295175
    [No Abstract]   [Full Text] [Related]  

  • 16. Emerging Role of PARP Inhibitors in Metastatic Prostate Cancer.
    Unlu S; Kim JW
    Curr Oncol Rep; 2022 Nov; 24(11):1619-1631. PubMed ID: 35931885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relevance of DNA damage repair in the management of prostate cancer.
    Banks P; Xu W; Murphy D; James P; Sandhu S
    Curr Probl Cancer; 2017; 41(4):287-301. PubMed ID: 28712484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer.
    Castro E; Romero-Laorden N; Del Pozo A; Lozano R; Medina A; Puente J; Piulats JM; Lorente D; Saez MI; Morales-Barrera R; Gonzalez-Billalabeitia E; Cendón Y; García-Carbonero I; Borrega P; Mendez Vidal MJ; Montesa A; Nombela P; Fernández-Parra E; Gonzalez Del Alba A; Villa-Guzmán JC; Ibáñez K; Rodriguez-Vida A; Magraner-Pardo L; Perez-Valderrama B; Vallespín E; Gallardo E; Vazquez S; Pritchard CC; Lapunzina P; Olmos D
    J Clin Oncol; 2019 Feb; 37(6):490-503. PubMed ID: 30625039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential Activity of PARP Inhibitors in
    Taza F; Holler AE; Fu W; Wang H; Adra N; Albany C; Ashkar R; Cheng HH; Sokolova AO; Agarwal N; Kessel A; Bryce A; Nafissi N; Barata P; Sartor AO; Bastos D; Smaletz O; Berchuck JE; Taplin ME; Aggarwal R; Sternberg CN; Vlachostergios PJ; Alva AS; Su C; Marshall CH; Antonarakis ES
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34778690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concordance of DNA Repair Gene Mutations in Paired Primary Prostate Cancer Samples and Metastatic Tissue or Cell-Free DNA.
    Schweizer MT; Sivakumar S; Tukachinsky H; Coleman I; De Sarkar N; Yu EY; Konnick EQ; Nelson PS; Pritchard CC; Montgomery B
    JAMA Oncol; 2021 Jun; 7(9):1-5. PubMed ID: 34086042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.